General Atlantic: Q3 2026 13F
Growth equity firm.
Holdings as of Sep 30, 2026 (Q3 2026)Filed Nov 13, 202613F deadline Nov 16, 2026 (45 days after quarter end)
Portfolio at a glance
Largest stock and ETF positions sized by weight, coloured by change since the previous 13F.
Biggest moves
Estimated dollars bought and sold in Q3 2026 (change in shares × quarter-end price).
Top buys
Ranked by estimated dollars added: change in shares × quarter-end price.
| Stock | Change | Est. $ |
|---|---|---|
KRSA Korsana | New | +$44M |
RSKD Riskified | Added+100% | +$42M |
Top sales
Ranked by estimated dollars sold, including full exits.
New positions
| Stock | Change | Est. $ |
|---|---|---|
KRSA Korsana | New | +$44M |
Sold out
| Stock | Change | Est. $ |
|---|---|---|
Revolution Medicines | Sold out | −$67M |
Largest holdings
Top 12 of 12 stock and ETF positions, as of Sep 30, 2026. Options are listed separately below.
| Stock | Change | Value |
|---|---|---|
DLO Dlocal | Trimmed-21.1% | $507M |
Chime | Trimmed-11% | $504M |
LFTO Liftoff Mobile | Unchanged | $400M |
XP Xp, Inc | Trimmed-12.7% | $377M |
ALKT Alkami | Unchanged | $265M |
SPTX Seaport Therapeutics | Unchanged | $123M |
RSKD Riskified | Added+100% | $84M |
NRIX Nurix Therapeutics | Unchanged | $72M |
PHVS Pharvaris | Trimmed-74.8% | $52M |
PBLS Parabilis Medicines | Unchanged | $50M |
KRSA Korsana | New | $44M |
GROV Grove Collaborative | Unchanged | $3M |
Source: GENERAL ATLANTIC, L.P., Form 13F-HR on SEC EDGAR, compared with the filing for Jun 30, 2026. 13F shows only US-listed long positions (plus listed options), is delayed up to 45 days, and estimated dollar changes assume the quarter-end price. Not investment advice. How we calculate this.